Gross-Goupil M - Search Results

1

Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma.

de Vries-Brilland M, Rioux-Leclercq N, Meylan M, Dauvé J, Passot C, Spirina-Menand E, Flippot R, Fromont G, Gravis G, Geoffrois L, Chevreau C, Rolland F, Blanc E, Lefort F, Ravaud A, Gross-Goupil M, Escudier B, Negrier S, Albiges L. de Vries-Brilland M, et al. J Immunother Cancer. 2023 Nov;11(11):e006885. doi: 10.1136/jitc-2023-006885. J Immunother Cancer. 2023. PMID: 37935564 Free PMC article.

2

[Revolution in treatment of renal carcinoma: molecular rational and clinical approach].

Escudier B, Gross-Goupil M. Escudier B, et al. Med Sci (Paris). 2008 Aug-Sep;24(8-9):697-9. doi: 10.1051/medsci/20082489697. Med Sci (Paris). 2008. PMID: 18789213 Free article. French. No abstract available.

3

Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

Loriot Y, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Bossi A, Fizazi K. Loriot Y, et al. Ann Oncol. 2009 Apr;20(4):703-8. doi: 10.1093/annonc/mdn694. Epub 2009 Jan 29. Ann Oncol. 2009. PMID: 19179557 Free article.

4

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

Fizazi K, Beuzeboc P, Lumbroso J, Haddad V, Massard C, Gross-Goupil M, Di Palma M, Escudier B, Theodore C, Loriot Y, Tournay E, Bouzy J, Laplanche A. Fizazi K, et al. J Clin Oncol. 2009 May 20;27(15):2429-35. doi: 10.1200/JCO.2008.18.9811. Epub 2009 Apr 13. J Clin Oncol. 2009. PMID: 19364971 Clinical Trial.

5

Sunitinib inducing tumor lysis syndrome in a patient treated for renal carcinoma.

Michels J, Lassau N, Gross-Goupil M, Massard C, Mejean A, Escudier B. Michels J, et al. Invest New Drugs. 2010 Oct;28(5):690-3. doi: 10.1007/s10637-009-9275-z. Epub 2009 Jun 24. Invest New Drugs. 2010. PMID: 19547920

6

Reflex sympathetic dystrophy in patients with metastatic renal cell carcinoma treated with everolimus.

Massard C, Fizazi K, Gross-Goupil M, Escudier B. Massard C, et al. Invest New Drugs. 2010 Dec;28(6):879-81. doi: 10.1007/s10637-009-9295-8. Epub 2009 Aug 1. Invest New Drugs. 2010. PMID: 19649567 No abstract available.

7

Incidence of brain metastases in renal cell carcinoma treated with sorafenib.

Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Massard C, et al. Ann Oncol. 2010 May;21(5):1027-31. doi: 10.1093/annonc/mdp411. Epub 2009 Oct 22. Ann Oncol. 2010. PMID: 19850637 Free article. Clinical Trial.

8

[New drugs in metastatic castration-resistant prostate cancer].

Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K. Albiges L, et al. Bull Cancer. 2010 Jan;97(1):149-59. doi: 10.1684/bdc.2009.1023. Bull Cancer. 2010. PMID: 20022854 French.

9

Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.

Ravaud A, Grossgoupil M. Ravaud A, et al. Lancet Oncol. 2010 Apr;11(4):307-8. doi: 10.1016/S1470-2045(10)70043-7. Lancet Oncol. 2010. PMID: 20359658 No abstract available.

10

[Renal cell carcinoma management and therapies in 2010].

Albouy B, Gross Goupil M, Escudier B, Massard C. Albouy B, et al. Bull Cancer. 2010;97:17-28. doi: 10.1684/bdc.2010.1067. Bull Cancer. 2010. PMID: 20418201 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

181 results

Search Page

Filters